IL28B Genotyping: A Step towards HCV-Personalized Therapy
International Journal of Gastroenterology Research and Practice
Recent discoveries in the field of genomics (IL28B genotyping) and therapeutics (direct acting antiviral agents [DAA]) have substantially increased the rate of sustained virological response (SVR) in HCV-infected patients. IL28B genotyping has been shown to be the strongest predictor of SVR in treatment-naïve HCV-genotype 1…